Manufacturing chimeric antigen receptor T cells: issues and challenges
Authors:
- 1 March 2019
- journal article
- research article
- Published by Elsevier in Cytotherapy
- Vol. 21 (3) , 327-340
Abstract
No abstract availableKeywords
Funding Information
- Seventh Framework Programme (602239 ATECT)
This publication has 75 references indexed in Scilit:
- Manufacture of Clinical-Grade CD19-Specific T Cells Stably Expressing Chimeric Antigen Receptor Using Sleeping Beauty System and Artificial Antigen Presenting CellsPLOS ONE, 2013
- CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic LeukemiaScience Translational Medicine, 2013
- Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T CellsScience Translational Medicine, 2012
- Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactorJournal of Translational Medicine, 2012
- Simplified Method of the Growth of Human Tumor Infiltrating Lymphocytes in Gas-permeable Flasks to Numbers Needed for Patient TreatmentJournal of Immunotherapy, 2012
- Reprogramming CD19-Specific T Cells with IL-21 Signaling Can Improve Adoptive Immunotherapy of B-Lineage MalignanciesCancer Research, 2011
- Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell TherapyJournal of Immunotherapy, 2009
- IL-7 and IL-15 allow the generation of suicide gene–modified alloreactive self-renewing central memory human T lymphocytesBlood, 2009
- Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cellsBlood, 2008
- Hematopoietic stem cell processing and cryopreservationJournal of Clinical Apheresis, 1992